Clinical Trial Update: Study of Efficacy of CDZ173 in Patients With APDS/PASLI [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial results for CDZ173 in APDS/PASLI and CVID have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Apds Pasli
• Common Variable Immunodeficiency

Drugs mentioned

• CDZ173 (CDZ173)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Common Variable Immunodeficiency (CVID), APDS / PASLI | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2022-03-11